Patents by Inventor Yat Sun Or

Yat Sun Or has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors
    Patent number: 11466033
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: October 11, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Brett Granger, Yong He, Guoqiang Wang, Yat Sun Or
  • Heterocyclic compounds as anti-viral agents
    Patent number: 11420976
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: August 23, 2022
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Yong He, Xuechao Xing, Guoqiang Wang, Ruichao Shen, Brett Granger, Jiang Long, Yat Sun Or
  • BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS
    Publication number: 20220227746
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: January 13, 2022
    Publication date: July 21, 2022
    Inventors: Kaicheng Zhu, Kevin McGrath, Solymar Negretti-Emmanuelli, Adam Szymaniak, Jianming Yu, In Jong Kim, Yat Sun Or
  • Benzodiazepine derivatives as RSV inhibitors
    Patent number: 11390631
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: July 19, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph Panarese, Yat Sun Or
  • Spiropyrrolidine derived antiviral agents
    Patent number: 11384090
    Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 20, 2021
    Date of Patent: July 12, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Ruichao Shen, Yong He, Xuri Gao, Jun Ma, Xuechao Xing, Hui Cao, Joseph D. Panarese, Yat Sun Or
  • Functionalized heterocycles as antiviral agents
    Patent number: 11377450
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: July 5, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joseph Panarese, Samuel Bartlett, Dexter Davis, Katherine Chong, Yat Sun Or
  • Functionalized peptides as antiviral agents
    Patent number: 11358953
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 9, 2021
    Date of Patent: June 14, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joseph D. Panarese, Dexter Davis, Nathaniel Thomas Kenton, Samuel Bartlett, Sean M. Rafferty, Yat Sun Or
  • Spiropyrrolidine derived antiviral agents
    Patent number: 11352363
    Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 20, 2021
    Date of Patent: June 7, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Xuri Gao, Ruichao Shen, Yong He, Jiajun Zhang, Joseph D. Panarese, Hui Cao, Xuechao Xing, Yat Sun Or
  • Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
    Patent number: 11345699
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: May 31, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Brett Granger, Guoqiang Wang, Ruichao Shen, Jing He, Yong He, Xuechao Xing, Jun Ma, Jiang Long, Bin Wang, Yat Sun Or
  • NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS
    Publication number: 20220162216
    Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 20, 2021
    Publication date: May 26, 2022
    Inventors: Guoqiang Wang, Ruichao Shen, Yong He, Xuri Gao, Jun Ma, Xuechao Xing, Hui Cao, Joseph D. Panarese, Yat Sun Or
  • NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS
    Publication number: 20220162231
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 22, 2021
    Publication date: May 26, 2022
    Inventors: Guoqiang Wang, Ruichao Shen, Jun Ma, Yong He, Xuechao Xing, Hui Cao, Xuri Gao, Xiaowen Peng, Joseph D. Panarese, Yat Sun Or
  • NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS
    Publication number: 20220162217
    Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 20, 2021
    Publication date: May 26, 2022
    Inventors: Guoqiang Wang, Xuri Gao, Ruichao Shen, Yong He, Jiajun Zhang, Joseph D. Panarese, Hui Cao, Xuechao Xing, Yat Sun Or
  • Spiropyrrolidine derived antiviral agents
    Patent number: 11339170
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 20, 2021
    Date of Patent: May 24, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Xuri Gao, Wei Li, Jiajun Zhang, Xiaowen Peng, Hui Cao, Jorden Kass, Ruichao Shen, Guoqiang Wang, Yat Sun Or
  • Spiropyrrolidine derived antiviral agents
    Patent number: 11325916
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 20, 2021
    Date of Patent: May 10, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Ruichao Shen, Yong He, Xuechao Xing, Matthew C. Rhodes, Guoqiang Wang, Yat Sun Or
  • Macrocyclic spiropyrrolidine derived antiviral agents
    Patent number: 11319325
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 20, 2021
    Date of Patent: May 3, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Jiajun Zhang, Xiaowen Peng, Joseph D. Panarese, Guoqiang Wang, Yat Sun Or
  • HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS
    Publication number: 20220119398
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: October 18, 2021
    Publication date: April 21, 2022
    Inventors: Yat Sun Or, Yong He, Kevin McGrath, Ruichao Shen, Adam Szymaniak, Xuechao Xing, In Jong Kim, Guoqiang Wang
  • TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20220119366
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: April 13, 2021
    Publication date: April 21, 2022
    Inventors: Guoqiang Wang, Ruichao Shen, Brett Granger, Jing He, Xuechao Xing, Yong He, Jiang Long, Jun Ma, Bin Wang, Yat Sun Or
  • FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS
    Publication number: 20220073499
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 9, 2021
    Publication date: March 10, 2022
    Inventors: Joseph D. Panarese, Dexter Davis, Nathaniel Thomas Kenton, Samuel Bartlett, Sean M. Rafferty, Yat Sun Or
  • Benzodiazepine derivatives as RSV inhibitors
    Patent number: 11254664
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: February 22, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Kaicheng Zhu, Kevin McGrath, Solymar Negretti-Emmanuelli, Adam Szymaniak, Jianming Yu, In Jong Kim, Yat Sun Or
  • FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS
    Publication number: 20220048944
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 12, 2021
    Publication date: February 17, 2022
    Inventors: Joseph D. Panarese, Dexter Davis, Nathaniel Thomas Kenton, Samuel Bartlett, Sean M. Rafferty, Yat Sun Or